Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.
Purity:
95.00%
CAS Number:
[2250440-41-4]
Target:
Complement System|||SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted